Ashish Kabir, MD
Clinical Neurophysiology · Dalton, GANPI 1053727396
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (29.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 28.4% of the total. 2025 is the largest year on record at $32,846, more than ten times the $3,148 reported in 2019.
Across 1,052 payments — averaging $78.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$24K
- UCB, Inc.$23K
- Argenx US, Inc.$10K
- Catalyst Pharmaceuticals, Inc.$6K
- Medtronic$3K
- Livanova USA, Inc.$2K
- plus $15K from 54 others
What the payments were for
- Consulting fees$24,25029%
- Speaking & faculty fees$24,60030%
- Travel & lodging$11,99214%
- Food & beverage$22,17227%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$22,149
- VYVGART HYTRULO$9,587
- Briviact$7,379
- Fycompa$5,463
- Fintepla$5,238
- VNS Therapy$1,787
- GENERAL DBS$1,064
- ACTIVA$974
- Percept$938
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$250
- GOCOVRI$189
- PERCEPT PC BRAINSENSE$136
- XCOPRI$135
- ANDEXXA$125
- UPLIZNA$125
- Vumerity$123
- Leqembi$119
How this compares
Too few clinical neurophysiology providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 70 | $410,670 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 25 | $264,036 |
| BriviactBrivaracetam | 126 | $209,834 |
| Austedo XrDeutetrabenazine | 29 | $198,852 |
| XcopriCenobamate | 142 | $178,632 |
| Nurtec OdtRimegepant Sulfate | 93 | $150,932 |
| IngrezzaValbenazine Tosylate | 18 | $133,610 |
| NuplazidPimavanserin Tartrate | 25 | $131,947 |
| Kesimpta PenOfatumumab | 15 | $128,508 |
| ZeposiaOzanimod Hydrochloride | 12 | $108,810 |
| UbrelvyUbrogepant | 65 | $80,375 |
| FycompaPerampanel | 67 | $73,338 |
| RytaryCarbidopa/Levodopa | 93 | $67,483 |
| Aimovig AutoinjectorErenumab-Aooe | 68 | $55,115 |
| Emgality PenGalcanezumab-Gnlm | 60 | $46,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam, Vimpat | $23,225 | $262,559193 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $440 | $198,85229 claims |
| SK Life Science, Inc.Xcopri | $735 | $178,632142 claims |
| PfizerNurtec Odt, Eliquis | $156 | $176,925133 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $468 | $150,04140 claims |
| AbbVieUbrelvy, Qulipta, Botox, Namzaric | $1,206 | $138,471119 claims |
| Acadia Pharmaceuticals IncNuplazid | $745 | $131,94725 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $114 | $108,81012 claims |
| Eisai Inc.Fycompa | $613 | $73,33867 claims |
| Amneal Pharmaceuticals LLCRytary | $825 | $67,48393 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $136 | $31,70222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Dalton
- Michael RivnerMacon$300K
- Kashyap PatelStatesboro$199K
- Joseph HormesMarietta$4K
- Sachin KedarAtlanta$3K
- Gregory EsperAtlanta$3K
- William RocheMacon$474
- Sara Ann Schleicher-DilksGainesville$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.